FindTrial
Sign In

Development and transformation of accurate diagnostic and therapeutic markers for hepatitis B-related hepatocellular carcinoma

Development and transformation of accurate diagnostic and therapeutic markers for hepatitis B-related hepatocellular carcinoma

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900020517
Enrollment
Unknown
Registered
2019-01-05
Start date
2017-12-02
Completion date
Unknown
Last updated
2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatitis B-related hepatocellular carcinoma

Interventions

Gold Standard:The pathology department diagnosed liver cancer
Index test:AFP-L3,&#32
FUC-GP73?FUC-HGF

Sponsors

Beijing Institute of Hepatology
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) the patient was confirmed as primary liver cancer by pathological examination; (2) the patient did not receive treatment before this treatment; (3) the patient has a surgical pointer; (4) patients are willing to accept questionnaire survey and answer all questions involved in this study; (5) the patients signed a written informed consent to participate in this study voluntarily.

Exclusion criteria

Exclusion criteria: Exclusion criteria: (1) patients with lung metastasis, colon cancer metastasis and other extrahepatic metastasis;(2) patients are not willing to participate in this study.

Design outcomes

Primary

MeasureTime frame
AFP-L3;FUC-GP73;FUC-GP73;—

Countries

China

Contacts

Public ContactLimin Zheng
zhenglm@mail.sysu.edu.cn+86 13533849550

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026